Logo_Biofrontera_AG.png
Biofrontera strengthens commercial focus with reorganization of its US business
January 06, 2020 09:00 ET | Biofrontera AG
Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced a new...
Logo_Biofrontera_AG.png
Extraordinary General Meeting of Biofrontera AG: Biofrontera Management Board supported by large majority
December 20, 2019 09:35 ET | Biofrontera AG
Leverkusen, Germany, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Logo_Biofrontera_AG.png
Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.
December 13, 2019 08:20 ET | Biofrontera AG
Leverkusen, Germany, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
Logo_Biofrontera_AG.png
Biofrontera to Participate in Upcoming Investor Conferences
November 22, 2019 11:06 ET | Biofrontera AG
Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its...
Logo_Biofrontera_AG.png
Biofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance
November 19, 2019 03:25 ET | Biofrontera AG
Leverkusen, Germany, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its...
Logo_Biofrontera_AG.png
Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
November 06, 2019 05:30 ET | Biofrontera AG
Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo_Biofrontera_AG.png
Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
October 23, 2019 02:00 ET | Biofrontera AG
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with...
Logo_Biofrontera_AG.png
Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
October 10, 2019 05:15 ET | Biofrontera AG
Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical...
Logo_Biofrontera_AG.png
Biofrontera to present at the Baader Investment Conference
September 17, 2019 09:45 ET | Biofrontera AG
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that Prof....
Logo_Biofrontera_AG.png
Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck
September 17, 2019 05:45 ET | Biofrontera AG
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label...